A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic mutation—KRAS circulating tumor DNA (ctDNA)—strongly indicates a higher risk of cancer ...

City of Hope researchers demonstrate proof of concept for a novel targeted therapy for pancreatic cancer, exploiting transcription-replication conflicts to combat treatment resistance.

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy. Adding immunotherapy to a new type of ...

For patients without the KRAS mutation (approximately 10% of cases ... are associated with a more biologically aggressive pancreatic cancer," says Jennifer Leiting, M.D., hepatobiliary and ...

Researchers at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S.

Nearly 90 percent of pancreatic cancers are driven by KRAS mutations, the most common cancer-causing gene mutation across cancer types, which researchers long considered "undruggable." ...

A new study focused on transcription-replication conflicts, which occur when mechanisms responsible for gene expression and ...

18, 2025 — Pancreatic cancer (PC) is the worst prognosis ... 2, 2024 — A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma ...

A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic mutation — KRAS circulating tumor DNA (ctDNA) — strongly indicates a higher risk of ...

A dding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

While mutations in the KRAS protein are known to drive pancreatic cancer, these do not appear to be sufficient to promote the transition from precancerous lesions to cancer, Tonelli noted.

These inhibitors use a different mechanism of action than most other KRAS inhibitors ... and another type of RAS mutation emerges, the treatment may not necessarily stop working,” Vonderheide ...